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A b s t r a c t
Introduction: The hormone leptin, which is produced in the adipose tissue, 
may influence tumorigenesis directly via its receptor (Ob-R). Thus, a  role 
for Ob-R in endometrial carcinogenesis has been proposed. However, most 
studies neither included samples of the entire histological progression of 
endometrial carcinoma nor examined Ob-R jointly with the estrogen and 
progesterone receptors (ER and PR, respectively). 
Material and methods: To determine the fluctuations of Ob-R, ER, and PR 
during the histological progression of endometrial carcinoma, we assessed 
their expression via immunohistochemistry (IHC) in six histological types of 
endometrium (proliferative, secretory, nonatypical and atypical hyperplasia, 
and endometrioid and nonendometrioid endometrial carcinoma), in which 
we performed histopathological and digital scoring for the quantification of 
receptors. 
Results: We found that Ob-R expression was positively correlated with that 
of ER and PR (r = 1, p < 0.001; r = 0.943, p < 0.005, respectively), and there 
was a significant difference in Ob-R expression among proliferative normal 
endometrium, hyperplasias, and carcinomas, according to their relative digi-
tally scored Ob-R expression (p < 0.001). In addition, we observed that Ob-R 
expression in the secretory endometrium was more similar to that of carci-
nomas than to its proliferative counterpart. 
Conclusions: These results indicate that Ob-R expression fluctuates during 
endometrial carcinogenesis in correlation with ER and PR, suggesting that 
Ob-R expression in vivo is highly dependent on estrogen and progesterone 
activities in the endometrium and on its ER and PR status, as suggested 
previously by in vitro studies. 
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Introduction
Epidemiological studies have shown that obesity is associated with in-
creased risk of several cancer types, including endometrium [1]. In Mexi-
co, endometrial carcinoma is the fifth cause of cancer deaths in adult fe-
males and its incidence is increasing [2]. Obesity is associated with both 
an increased risk of developing endometrial carcinoma (it accounts for 
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approximately 60% of the incidence of this condi-
tion) and a worse prognosis after disease diagno-
sis [1, 3, 4]. Potential mechanisms linking obesity 
to cancer are complex and not well understood. 
Previous attempts to explain the effects of obesi-
ty on endometrial carcinogenesis were centered 
mainly on the increased levels of circulating serum 
estrogens and deficiency in progesterone levels. 
Therefore, changes in the expression of both the 
estrogen and progesterone receptors (ER and PR, 
respectively) during the histological progression of 
endometrial carcinoma are well documented [5].
It has been established that fat tissue is an 
endocrine organ that produces and secretes 
polypeptide hormones, adipokines, among which 
leptin is the most abundant [6]. Leptin is positive-
ly correlated with adipose stores and nutritional 
status, and important in energy balance and ap-
petite control [7, 8]. Research over the past few 
years has suggested leptin/leptin receptor (Ob-R) 
dysregulation to have a  role in the development 
of a large variety of malignancies by activation of 
PI3K, MAPK, and STAT3 pathways [9]. Leptin induc-
es production of inflammatory cytokines (tumor 
necrosis factor (TNF) α and interleukin (IL) 6) by 
macrophages, especially in obese individuals. This 
low-grade inflammation in individuals with meta-
bolic syndrome in turn increases the risk of obesi-
ty-related diseases and cancer [10].
Moreover, hyperleptinemia is a  common fea-
ture of obese women, who have a higher risk of 
endometrial cancer than women with normal 
weight, thus implying a direct role of the adipose 
tissue, via the hormone leptin [11].
Leptin through Ob-R activation has direct effects 
on proliferation, invasion, and production of angio-
genic proteins in cancerous endometrial cells, and 
leptin actions are dose dependent and proportional 
to the expressed amount of Ob-R [9, 12, 13]. 
Several studies of human endometrial carcino-
ma have suggested that Ob-R is downregulated in 
the endometrium and might be related to its dif-
ferentiation status [14, 15], which resembles the 
behavior of ER and PR [16].
Furthermore, Ob-R expression has been shown 
to be closely related to endometrial histology (i.e., it 
varies according to disease or the menstrual phase) 
and body mass index (BMI) [17–19]. In fact, spe-
cifically, obesity increases the risk of development 
of a particular histological subtype, endometrioid 
endometrial carcinoma [20], and its precursor le-
sion, atypical endometrial hyperplasia [21]. How-
ever, most studies neither clearly differentiated 
the histological subtype of samples over the pro-
gression of endometrial carcinoma nor examined 
jointly Ob-R, ER, and PR expression. Taken togeth-
er, the aforementioned aspects might contribute 
to the limitations of the current findings, such as 
the reported lack of differences in the expression of 
Ob-R between normal and endometrial cancerous 
tissues [18]. Thus, the aim of this study was to as-
sess the expression of Ob-R, ER, and PR via immu-
nohistochemistry (IHC) in normal, hyperplasic, and 
endometrial cancerous tissues to increase knowl-
edge and obtain a better prognostic value during 
the progression of endometrial carcinoma.
Material and methods
Study population
Paraffin-wax-embedded blocks of endometrial 
biopsies and clinicopathological data from 108 pa-
tients were recovered by examining files of the Pa-
thology Department located in the archives of the 
Mexican Institute of Social Security (IMSS), Hospi-
tals No. 23, Gynecology and Obstetrics, and No. 25, 
High Specialty Medical Unit, which are both locat-
ed in Monterrey, Nuevo León, Mexico, during the 
2004–2006 period. Endometrial biopsies were car-
ried out in compliance with the indications reported 
by physicians. The tissues were fixed in 4% formalin 
and embedded in paraffin wax. The mean patient 
age was 48 years (range: 38–71 years) and their 
mean BMI was 32 kg/m2 (range: 21–46). None of 
the patients had a history of exogenous hormone 
therapy prior to the procedure. Endometrial histol-
ogy was evaluated in sections that were stained 
with hematoxylin and eosin (H&E) to confirm the 
initial histological diagnosis [22] and to select an 
adequate region for IHC. An expert pathologist as-
signed the menstrual cycle stage of the samples 
according to an idealized 28-day menstrual cycle 
for the normal endometrium group, which con-
sisted of 10 biopsies of the proliferative stage and 
20 biopsies of the secretory stage [22]. The hyper-
plasia group was divided into 19 biopsies of endo-
metrial hyperplasia and 25 biopsies of nonatypical 
hyperplasia [23]. In the carcinoma group, the seg-
regation was made according to histological type, 
yielding 23 biopsies of type 1 endometrioid endo-
metrial carcinoma and 11 biopsies of type 2 non-
endometrioid endometrial carcinoma [24]. Table I 
describes in detail the clinicopathological data of 
the six histological types of endometrial tissues. 
The Ethics Committee of the National Research 
Commission of the IMSS in Mexico City approved 
this study (registration number R-2012-785-011).
Immunohistochemistry
Sections (4 mm) were cut from the blocks and 
placed on silanized slides (S3002; Dako North 
America Inc., Carpinteria, CA, USA). These were 
dewaxed in xylol three times, 10 min each, hy-
drated in a  decreasing series of ethanol, and 
washed with distilled water. Antigen recovery 
was performed by heating samples to 96°C for 
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20 min in S1699 solution (all solutions used for 
IHC were from Dako North America Inc, or as 
specified otherwise). These were then allowed 
to cool at room temperature for an additional 
20 min. The slides were washed with S1968 buf-
fer for 5 min, followed by placement in S2001 
(which is an endogenous peroxidase-blocking 
solution) and 15 min incubation in X0909 solu-
tion, to reduce nonspecificity. Tissue sections 
were then incubated with the appropriate primary 
antibodies (anti-Ob-R sc-80255 (which covers all 
isoforms), anti-ER SC-56836, and anti-PR SC-810; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 
1 : 150, 1 : 300, and 1 : 100 dilutions, respectively, 
in a wet chamber for 20 h at 4°C. As a negative 
control, the primary antibody was replaced with 
1% albumin in phosphate-buffered saline. A sam-
ple of breast cancer tissue that consistently ex-
hibited a 3+ intensity after several repetitions of 
the experiment was taken as a positive control, to 
ensure the validity of the IHC procedure. The sam-
ples were incubated for 30 min in the K0690 bi-
otinylated universal antibody, followed by a 5 min 
wash with buffer and incubation with the K0690 
streptavidin–horseradish peroxidase complex for 
30 min at room temperature. Specific reactivity 
was visualized by incubation with K3468 (3,3′-di-
aminobenzidine tetrahydrochloride (DAB)) for 
10 min, followed by immersion in 0.5% CuSO
4 for 
2 min. The slides were stained with S3309 H&E for 
1 min, dehydrated in an ethanol series, clarified in 
xylol, and mounted on synthetic resin (HX787224; 
Merck, Darmstadt, Germany).
IHC scoring
A trained histopathologist carried out IHC scor-
ing. Staining intensity was classified according to 
the following criteria: 0, negative immunostain-
ing; 1+, weak staining in at least 25% of cells; 2+, 
moderate expression in 25–50% of cells; and 3+, 
strong expression in ≥ 50% of the cells [25, 26]. 
The histopathologist assigned a  histopathologi-
cal score to the endometrial tissue in its entirety, 
to evaluate the expression of Ob-R, ER, and PR in 
the 108 tissues included in the study. The score 
corresponded to that observed in the functional 
glandular epithelium.
A  digital score was also obtained because 
of its reported advantages over the histological 
score, i.e., it is more appropriate for the quanti-
tative analysis of IHC with color enzyme reaction, 
especially those that use DAB, and it affords the 
most sensitive detection of antigen content [27]. 
All slides were visualized using an Olympus BX41 
microscope (Olympus America, Inc., Melville, NY, 
USA) at 320× magnification, and images were 
captured with a  Nikon D40 camera (Nikon, Inc., 
Melville, NY, USA). Images were digitized using the 
ImageJ software (NIH ver. 1.45p; National Insti-
tutes of Health, Bethesda, MD, USA), followed by 
an analysis that included the use of the rolling ball 
algorithm and region of interest (ROI) extraction 
(functional glandular epithelium); finally, we used 
a  color deconvolution algorithm to distinguish 
the contributions of the DAB and H&E stains, 
which allowed the independent measurement 
of a specific stain in areas with staining overlap 
by determining the amount and density of each 
component color channel that is required to make 
up the recorded color of a pixel. This algorithm re-
ports the positive percent in a region for a given 
staining component in three light-transmission 
intensity thresholds and the average optical den-
sity of that stain. The image derived from DAB was 
analyzed to obtain the median optical density val-
Table I. Clinicopathological data of the six histological types of endometrial tissues












Pre Post 1 2 3 Low High < 5 > 5 
10 Proliferative 
endometrium
41.7 ±3.9 27.6 ±2.5 10 0 – – – – – – –
20 Secretory 
endometrium
42.6 ±3.4 29.8 ±2.9 20 0 – – – – – – –
25 Non-atypical 
hyperplasia
45.6 ±5.3 31.0 ±4.8 16 9 – – – – – – –
19 Atypical hyperplasia 45.2 ±10.6 31.7 ±5.1 13 6 – – – – – – –
23 Endometrioid 
carcinoma
54.8 ±14.8 36.0 ±5.9 7 16 8 12 3 19 4 12 11
11 Non-endometrioid 
carcinoma
54.4 ±17.1 32.2 ±7.1 3 8 0 0 11 10 1 5 6
108 Total 47.5 ±11.2 31.8 ±5.5
BMI – body mass index, menopausal status: pre- or postmenopausal, clinical stage: low (I–II), high (III–IV). 
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ue, with a  range of 0–255 (black to white) [27]. 
A  lower antigen content was associated with an 
optical density closer to 255 [28]. A digital score 
was assigned to the glandular epithelium, which 
was characteristic of the IHC score designated in 
each of the cases for the expression of Ob-R, ER, 
and PR in the 108 tissues included in the study.
Statistical analysis
The database was captured in the IBM SPSS sta-
tistical package (v. 22; IBM Corporation, Armonk, 
NY, USA). The results obtained for the three mark-
ers (Ob-R, ER, and PR) in the six histological types 
were processed for association in two ways: for 
qualitative information (histopathological score), 
Fisher’s exact test was applied; for quantitative in-
formation (digital scoring), the Kruskal-Wallis and 
the Student-Newman-Keuls (SNK) tests were per-
formed. To determine the relationship between 
Ob-R and ER and PR, Spearman’s correlation coef-




No statistically significant differences were 
found in the immunohistochemical determination 
of Ob-R, ER, and PR among the six endometrial 
tissues studied according to the histopathologi-
cal scoring, as per Fisher’s test. Ob-R expression 
was observed as cytoplasmic staining, with a 2+ 
score in tissues of the proliferative endometrium, 
in both hyperplasia groups, and in endometrioid 
carcinomas, and a clear diminution to 1+ was ob-
served in the secretory endometrium and nonen-
dometrioid carcinomas. ER expression exhibited 
a 3+ score in the proliferative endometrium and 
in both hyperplasia groups, a 2+ score in endome-
trioid carcinomas, and a 1+ score in the secretory 
endometrium and nonendometrioid carcinomas. 
PR expression reached a 2+ score in the prolifer-
ative endometrium and nonatypical hyperplasia; 
in contrast, in atypical hyperplasias and endome-
trioid carcinomas, it dropped to a  1+ score, and 
exhibited a negative score in the secretory endo-
metrium and nonendometrioid carcinomas. Both 
ER and PR showed characteristic nuclear staining. 
Table II lists the immunohistochemical expression 
of Ob-R, ER, and PR in the six histological types of 
endometrial tissues included in the study, and Fig-
ure 1 includes a representative image of the IHC 
reactions observed for Ob-R, ER, and PR in the six 
histological types of endometrial tissues studied 
here.
Digital scoring
The mean values of Ob-R expression observed 
in the samples studied here showed that tissues 
exhibited statistically significant differences in 
the levels of this protein and can be subgrouped 
in the categories according to the Kruskal-Wallis 
(p < 0.000) and SNK tests (Table II). The first group 
corresponded to the proliferative endometrium, 
which expressed the highest content of the pro-
tein. The second group corresponded to nonatyp-
ical and atypical hyperplasias, and the third group 
included the endometrioid carcinomas, secretory 
endometrium, and nonendometrioid carcinomas 
and expressed the lowest amount of Ob-R.
Similarly, ER expression showed statistically 
significant differences according to the same test 
(Table II); one group corresponded to the prolifera-
tive endometrium and both types of hyperplasias, 
and the other group, which exhibited the lowest 
expression level of the protein, included both types 
of carcinomas and the secretory endometrium. 
The expression of PR was also significantly dif-
ferent among the samples examined. It exhibited 
the lowest expression level among the proteins 
Table II. Immunohistochemical expression of Ob-R, ER and PR in the six histological types of endometrial tissues
N Histological diagnosis Histopathologicala Digital score (median ± SD)b
Ob-R ER PR Ob-R* ER** PR***
10 Proliferative endometrium (PE) (++) (+++) (++) 26 ±9 30 ±13 113 ±45
20 Secretory endometrium (SE) (+) (++) (–) 143 ±29 153 ±56 208 ±44
25 Non-atypical hyperplasia (NAH) (++) (+++) (++) 87 ±35 33 ±21 162 ±67
19 Atypical hyperplasia (AH) (++) (+++) (+) 98 ±34 42 ±22 161 ±59
23 Endometrioid carcinoma (EEC) (++) (++) (+) 141 ±64 132 ±81 205 ±47
11 Non-endometrioid carcinoma (NEC) (+) (+) (–) 177 ±68 214 ±37 224 ±41
Kruskal-Wallis test p < 0.001 p < 0.001 p < 0.001
aHistopathological score is shown as average per group; bDigital score is shown as the optical median value of groups ± SD. SNK 
test: *PE ≠ SE ≠ NAH =AH ≠ EEC = NEC; **PE ≠ SE ≠ NAH = AH ≠ EEC ≠ NEC; ***PE ≠ SE ≠ NAH = AH ≠ EEC = NEC. Spearman correlation: 
Ob-R vs. ER (r = 1, p < 0.0001), Ob-R vs. PR (r = 0.943, p < 0.005). Ob-R – leptin receptor, ER – estrogen receptor, PR – progesterone receptor.
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Figure 1. Representative examples of IHC signals for Ob-R, ER, and PR in the six histological types of endometrial 
tissues studied here. For illustrative purposes, the tissues were ordered according to their relative expression score 
(high to low score for Ob-R)
Ob-R – leptin receptor, ER – estrogen receptor, PR – progesterone receptor, PE – proliferative endometrium, NAH – nonatypical 
hyperplasia, AH – atypical hyperplasia, EEC – endometrioid carcinoma, SE – secretory endometrium, NEC – nonendometrioid 
endometrial carcinoma.
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analyzed here, and was subgrouped in the same 
manner as that described for Ob-R (Table II) (prolif-
erative endometrium, nonatypical and atypical hy-
perplasia, endometrioid carcinomas, proliferative 
endometrium, and nonendometrioid carcinomas).
Finally, Spearman’s correlation indicated that 
Ob-R expression was positively correlated with the 
expression of both ER (r = 1, p < 0.0001) and PR 
(r = 0.943, p = 0.005).
Discussion
Increased serum leptin levels is a  common 
feature of obese women at risk of developing 
endometrial carcinoma [11]. Leptin effects on 
proliferation and invasion in cancerous endome-
trial cells are dose dependent and proportional to 
the expressed amount of Ob-R [9, 12, 13]. Thus 
its behavior during the progression of endometri-
al carcinoma might be related to the histological 
features of tissues. 
We found that the leptin receptor was down-
regulated during the histological progression of 
endometrial carcinoma, and that its expression 
was correlated with both the estrogen and proges-
terone receptors. We also found that Ob-R expres-
sion was clearly opposite between the two normal 
endometrial phases included in the study: the pro-
liferative and secretory endometrium. As reported 
previously, we found that Ob-R was downregulated 
in parallel with endometrial dedifferentiation (data 
not shown) and was diminished in tumor-tissue 
zones compared with histologically normal tissue 
zones of the same patient [14]. We also found that 
endometrial tumors with a solid appearance (high-
er histological grade) tended to have lower Ob-R 
expression compared with those that were well 
differentiated [15]. Moreover, we provide evidence 
that both types of endometrial cancer lost Ob-R 
expression markedly compared with the prolifer-
ative endometrium, which was in contrast with 
a previous report of a lack of significant differences 
between normal proliferative tissues and cancer-
ous tissues of the endometrium [18].
Furthermore, we found that Ob-R expression 
in hyperplasias was among cancerous and prolif-
erative tissues. This was in line with a model of 
Ob-R downregulation during the progression of 
endometrial carcinoma because these lesions are 
considered the precursors of endometrioid carci-
noma [29].
In addition, we showed that the normal prolif-
erative and secretory phases of the endometrium 
exhibited contrasting levels of Ob-R, with the high-
est expression observed in the proliferative phase, 
and a  marked reduction in the secretory phase. 
Furthermore, we found that Ob-R expression in 
the proliferative phase was associated to a greater 
extent with hyperplasias compared with the secre-
tory phase. Similarly, the secretory phase exhibit-
ed a greater equivalence with carcinomas than it 
did with the proliferative phase, which clarified its 
status between the normal endometrial phases. 
This result was in contrast with the reported max-
imal expression of Ob-R RNA levels in the secreto-
ry stage [17]; however, RNA expression does not 
necessarily match protein levels [30], which might 
have been the case here. Otherwise, the low lev-
els of the Ob-R protein observed in the secretory 
phase were consistent with the reported effects of 
progesterone on its downregulation [31].
The reported levels of Ob-R are in line with the 
experimental evidence of the mitogenic effects of 
leptin [9], given that the higher levels of Ob-R were 
found in proliferative and hyperplasic tissues. In 
contrast, in cancerous tissues Ob-R expression is 
downregulated, which is in agreement with the 
progression toward the independence of hor-
mones in endometrial tumors [32].
Furthermore, we report for the first time a cor-
relation between Ob-R and ER and PR during en-
dometrial carcinogenesis. This implies that Ob-R 
expression is regulated by those hormones. Al-
though this phenomenon is not understood com-
pletely, fluctuations in Ob-R may be caused by 
positive dose-dependent regulation of estrogens 
by the expression of leptin and Ob-R through di-
rect ER activation [33], whereas the regulation of 
progesterone through the activation of PR dimin-
ishes its expression [31]. This might explain the 
high Ob-R levels observed in hyperplasias and 
proliferative endometrium because both are char-
acterized by conditions of high estrogen and low 
progesterone levels, including a loss of PR expres-
sion in hyperplasias [3]. In addition, those tissues 
also possess high leptin levels. However, in con-
trast with the downregulation of Ob-R in the nor-
mal secretory phase in patients with hyperplasias, 
hyperleptinemia may account for an even greater 
hormonal misbalance and enhance carcinogene-
sis in obese patients.
These results are supported by the effects of 
hyperleptinemia in normal follicular development 
and ovulation, including the disruption of normal 
menstrual cycles [34]. Moreover, women diag-
nosed with atypical hyperplasia have a 10 times 
greater probability of developing carcinomas [35].
The results obtained here for ER and PR reaffirm 
previous studies in which the IHC signals of these 
proteins were diminished in carcinomas compared 
with normal endometrial tissues and hyperplasias. 
Moreover, the best-differentiated carcinomas ex-
hibited a greater expression level of both receptors 
compared with poorly differentiated tumors [36].
The limitations of the present study must be 
considered when interpreting its results. First, we 
used a digital scoring approach for the analysis of 
DAB staining because of the reported advantages 
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of this method, which enhanced the chances of 
capturing subtle changes in antigen content [27]. 
Second, the antibody used for Ob-R detection re-
acts with all isoforms of the protein, whereas the 
effects of leptin are restricted to the Ob-Rb iso-
form – the only one that possesses signal-trans-
ducing capabilities [37]. Finally, we did not assess 
serum hormone levels in the patients included in 
the present study. Despite these limitations, we 
clarified the pattern of expression of the Ob-R 
protein during the histological progression of en-
dometrial carcinoma, which had not been report-
ed previously. We clearly differentiated the histo-
logical subtypes of samples over tumorigenesis: 
control groups, proliferative and secretory endo-
metrium, atypical and nonatypical hyperplasia, 
and endometrial carcinoma types I and II. We re-
ported for the first time the correlation between 
Ob-R and the receptors of the steroid hormones 
estrogen and progesterone, which are currently 
the most valuable prognostic biomarkers of this 
neoplasia [38].
In conclusion, during the progression of endo-
metrial carcinoma, Ob-R was downregulated and 
was correlated with ER and PR expression. How-
ever, its overexpression in hyperplasias might en-
hance its susceptibility to malignancy in patients 
with obesity because of hyperleptinemia. More-
over, although Ob-R expression appeared to be 
regulated by estrogen and progesterone, during 
carcinogenesis, the expression of the three mark-
ers was lost altogether after the differentiation 
of endometrial tissues. The analysis of Ob-R to-
gether with hormone receptors suggests that the 
assessment of these receptors in endometrial 
carcinoma has a  better prognostic value than 
does the analysis of Ob-R and hormone recep-
tors alone.
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